Latest News
Alkermes plc
- Alkermes Public Limited Company Estimates – MUN:8AK
- Alkermes to Report Third Quarter Financial Results on November 3, 2026
- Press Release: Alkermes to Report Third Quarter Financial Results on November 3, 2026
- Alkermes (ALKS) Climbs 2.79% to $41.22 as Buyers Test Upper Range - Rectangle Pattern
- Alkermes to Present New Data on Alixorexton and LUMRYZ® (sodium oxybate) at Sleep Europe 2026, Underscoring Leadership in Sleep Medicine Research
- Alkermes to present sleep medicine data at European congress By Investing.com
- Form 4 Alkermes plc. For: 12 October By Investing.com
- ViewPoints: Alkermes ADHD data offer first test of orexin as 'GLP-1 of the brain'
- Alkermes eyes growth with LUMRYZ's new idiopathic hypersomnia use after positive Phase 3 results
- Alkermes: Idiopathic Hypersomnia Could Expand LUMRYZ Into A Larger Growth, Margin Driver
- Alkermes Fails to Fend Off Addiction Treatment Antitrust Claim
- Value Drug plausibly alleges Alkermes duped USPTO, judge says in antitrust suit
Headlines from the last 30 days, linking to the original publishers. See all market news →